40 results
Page 2 of 2
8-K
EX-99.1
gfn9u4b 4dnp02xbls5k
8 May 12
Regeneron and Bayer Announce Co-Promotion Agreement With Santen For EYLEA® (aflibercept) Injection in Japan
12:00am
8-K
EX-99.1
52983
5 Dec 11
Two Year Results of Phase 3 Studies with EYLEA™ (aflibercept) Injection in wet AMD Show Sustained Improvement in Visual Acuity
12:00am
8-K
EX-99.1
8k65nq
27 Apr 11
Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Second Phase 3 Study in Central Retinal Vein Occlusion
12:00am
8-K
EX-99.1
qf0bqa
20 Dec 10
Other Events
12:00am
8-K
EX-99.1
tba92 7g4o3k
22 Nov 10
Bayer and Regeneron Report Positive Top-Line Results of Two Phase 3 Studies with VEGF Trap-Eye in Wet Age-related Macular Degeneration
12:00am
8-K
EX-99.1
f1oj pklcauxs6
2 Mar 07
Regeneron Reports Fourth Quarter and Full Year 2006 Financial and Operating Results
12:00am
8-K
EX-99.1
cduduwtvoc6ry61uz0ly
7 Nov 06
Regeneron Reports Third Quarter Financial and Operating Results
12:00am
8-K
EX-99.1
civjljy
3 Aug 06
Regeneron Reports Second Quarter Financial and Operating Results
12:00am
8-K
EX-99
2bb20gla 4iy6ogw9m
5 May 06
Results of Operations and Financial Condition
12:00am
8-K
EX-99.1
kfzf9hrpu m6zk39fyon
26 Sep 05
Cost Associated with Exit or Disposal Activities
12:00am
8-K
39s7iih5kg6ilwu0sz
26 Sep 05
Cost Associated with Exit or Disposal Activities
12:00am
10-K
hco1w
26 Mar 97
Annual report
12:00am